Related news from
Mon, 01 Apr 2024 13:09:00 +0000	InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million NEW YORK & HERZLIYA, Israel, April 01, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2023. All amounts are expressed in New Israeli Shekels (NIS), unless otherwise noted.
Fri, 22 Mar 2024 15:58:00 +0000	InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint NEW YORK & HERZLIYA, Israel, March 22, 2024--InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company outside of North America, is thrilled to congratulate The Federal Republic of Germany for the passing of the "CannG" Cannabis Act, which is expected to take effect on April 1, 2024. On the backdrop of this monumental development, InterCure expects to launch a series of products in Germany in the coming months.
Tue, 13 Feb 2024 21:46:00 +0000	InterCure Provides an Update Regarding Nir Oz Facility NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on October 17, 2023, in which the Company provided an update regarding the status of the security situation in Israel, and its impact on the Company and its employees, the Company is providing an additi
Wed, 31 Jan 2024 14:27:00 +0000	InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, announced today that it has entered into a share purchase agreement (the “Agreement”) with the shareholders of Leon Pharm Ltd. (the “Sellers”, and “Leon Pharm”, respectively) to purchase Leon Pharm, a leading, Israel-based pharmacy chain specializing in dispensing med
Tue, 31 Oct 2023 20:39:00 +0000	InterCure Wins Cannolam Arbitration Proceeding NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“
Tue, 17 Oct 2023 21:04:00 +0000	InterCure Provides an Update Regarding the Security Situation in Israel NEW YORK, and HERZLIYA, Israel, Oct. 17, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel and outside of North America, today addressed the status of the security situation in the State of Israel, and its impact on the Company and its employees. On October 7, 2023, Hamas terrorists infiltrated Israel’s southern border (the “Israeli Southern Border”) from the Gaza Strip and conducted a
Thu, 31 Aug 2023 23:45:00 +0000	InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY Half Year Revenues 2020 to 2023 Half Year Revenues 2020 to 2023 Achieved record revenues of NIS 209 million ($75 million)1 for the first half of 2023 Annualized revenue run rate of NIS 417 million ($149 million) Adjusted EBITDA2 of NIS 30 million ($11 million) Generated NIS 35 million ($13 million) cash from operations in the second quarter Strong balance sheet with over NIS 116 million ($42 million) cash and financial assets3 of NIS 71 million ($25 million) NEW YORK and HERZLIYA, Israel, Aug. 3
Mon, 10 Jul 2023 21:00:00 +0000	InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE NEW YORK and TORONTO and HERZLIYA, Israel, July 10, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), announced today that its board of directors (“Board”) has approved the voluntarily delisting of the Company’s common shares (“Shares”) from the Toronto Stock Exchange (the “TSX”) (the “Delisting”). The Company has decided to delist from the TSX after concluding that maintaining the listing does not offer substantial ben
Fri, 09 Jun 2023 21:18:00 +0000	InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger NEW YORK and TORONTO and HERZLIYA, Israel, June 09, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company"), reports today that, further to the Company’s press release issued on February 1, 2023, where the Company had reported the termination of the merger agreement (the “Agreement”) with Cann Pharmaceutical Ltd. ("Better") due to fundamental disagreements between the parties thereto and that the closing conditions contained i
Mon, 15 May 2023 21:59:00 +0000	InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference Mr. Rabinovitch is one of the global cannabis senior executives to participateNEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)("InterCure") today announced that Alexander Rabinovitch, CEO of InterCure, will participate in the Cowen 3rd Annual European Cannabis Conference, taking place May 16th, 2023 in Berlin, Germany. Mr. Rabinovitch will take part in the European Frontier Markets & Israel panel on M
Mon, 15 May 2023 21:45:00 +0000	InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY Quarterly Annualized Revenue Quarterly Annualized Revenue Achieved record revenues of $40 million for the first quarter Annualized revenue run rate of $159 million Adjusted EBITDA(1) of $6 Million Strong balance sheet with over $45 million cash and Net current assets of over $72 million NEW YORK, TORONTO, and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc)(“InterCure” or the “Company”) is pleased to announce its financial
Mon, 15 May 2023 12:30:00 +0000	InterCure to Be Featured with Mike Tyson in an Exclusive Interview on Fox Business The Company will be featured on the Claman Countdown show on Monday to discuss its strong 2022 results and recent partnership with Mike TysonNEW YORK and TORONTO and HERZLIYA, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) ("InterCure'' or the "Company"), the largest and fastest growing medical cannabis company outside of North America, is pleased to announce that its Chairman and former Prime Minister of Israel Mr. Ehud Barak will be featured in an exclusive